Phase 1 and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
CONCLUSIONS: DKN-01 300mg was well tolerated in this combination but did not appear to have additional activity beyond historically reported efficacy with gemcitabine/cisplatin alone. Exploratory pharmacokinetic and biomarker data indicate potential antiangiogenic and immunomodulatory activity of DKN-01/chemotherapy and the need for increased dose/intensity. A study with DKN-01 600mg in combination with a PD-1 inhibitor in BTC is ongoing.
PMID: 32878766 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA, Miksad R, Mahalingam D, Zhu AX, Duda DG Tags: Clin Cancer Res Source Type: research
More News: Anemia | Bile Duct Cancer | Cancer | Cancer & Oncology | Chemotherapy | Cholangiocarcinoma | Gallbladder Cancer | Study | Thrombocytopenia | Toxicology